Concomitant Resistance in Murine Tumours
Author Information
Author(s): M Franco, OD Bustuoabad, PD di Gianni, A Goldman, CD Pasqualini, RA Ruggiero
Primary Institution: Instituto de Investigaciones Hematologicas, Academia Nacional de Medicina, Buenos Aires, Argentina
Hypothesis
Can immunogenic tumours induce a form of concomitant resistance similar to that demonstrated for non-immunogenic tumours?
Conclusion
The study suggests that both immunogenic and non-immunogenic tumours can induce a common serum-mediated mechanism of concomitant resistance at late stages of tumour development.
Supporting Evidence
- Two peaks of concomitant resistance were detected during tumour development.
- The first peak was tumour specific and T-cell dependent, while the second was non-specific and thymus independent.
- Serum from tumour-bearing mice exhibited growth-inhibitory activity on tumour cells in vitro.
- The intensity of the second peak of concomitant resistance correlated with serum inhibitory activity.
Takeaway
When mice have one tumour, they can sometimes fight off a second one, even if it's a different type. This study found that both types of tumours can help mice resist new tumours later on.
Methodology
The study involved various immunisation assays and tumour implantation in BALB/c mice, with subsequent analysis of serum factors and tumour growth.
Limitations
The study primarily focused on murine models, which may not fully translate to human conditions.
Participant Demographics
BALB/c mice of both sexes, aged 2-4 months.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website